SLFN11 and cancer: Given that phase 1 clinical trials with TAK-243 are underway in patients with advanced solid tumors and blood cancers (NCT02045095 and NCT03816319), our results imply that the expression status of SLFN11 might be utilized to predict therapeutic benefit of TAK-243 in cancer treatment.